Logo image of ERAS

ERASCA INC (ERAS) Stock Fundamental Analysis

NASDAQ:ERAS - Nasdaq - US29479A1088 - Common Stock - Currency: USD

1.49  +0.05 (+3.47%)

After market: 1.49 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ERAS. ERAS was compared to 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ERAS as it has an excellent financial health rating, but there are worries on the profitability. ERAS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ERAS had negative earnings in the past year.
ERAS had a negative operating cash flow in the past year.
ERAS had negative earnings in each of the past 5 years.
In the past 5 years ERAS always reported negative operating cash flow.
ERAS Yearly Net Income VS EBIT VS OCF VS FCFERAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

ERAS has a Return On Assets of -33.44%. This is in the better half of the industry: ERAS outperforms 63.08% of its industry peers.
ERAS's Return On Equity of -39.45% is fine compared to the rest of the industry. ERAS outperforms 70.79% of its industry peers.
Industry RankSector Rank
ROA -33.44%
ROE -39.45%
ROIC N/A
ROA(3y)-36.99%
ROA(5y)-43.38%
ROE(3y)-45.53%
ROE(5y)-51.63%
ROIC(3y)N/A
ROIC(5y)N/A
ERAS Yearly ROA, ROE, ROICERAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ERAS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERAS Yearly Profit, Operating, Gross MarginsERAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ERAS has been increased compared to 1 year ago.
ERAS has more shares outstanding than it did 5 years ago.
ERAS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ERAS Yearly Shares OutstandingERAS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ERAS Yearly Total Debt VS Total AssetsERAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of 0.85, we must say that ERAS is in the distress zone and has some risk of bankruptcy.
ERAS's Altman-Z score of 0.85 is fine compared to the rest of the industry. ERAS outperforms 65.05% of its industry peers.
There is no outstanding debt for ERAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.85
ROIC/WACCN/A
WACCN/A
ERAS Yearly LT Debt VS Equity VS FCFERAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 12.35 indicates that ERAS has no problem at all paying its short term obligations.
The Current ratio of ERAS (12.35) is better than 84.05% of its industry peers.
A Quick Ratio of 12.35 indicates that ERAS has no problem at all paying its short term obligations.
The Quick ratio of ERAS (12.35) is better than 84.05% of its industry peers.
Industry RankSector Rank
Current Ratio 12.35
Quick Ratio 12.35
ERAS Yearly Current Assets VS Current LiabilitesERAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.19% over the past year.
EPS 1Y (TTM)26.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ERAS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.03% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y36.32%
EPS Next 2Y13.89%
EPS Next 3Y9.95%
EPS Next 5Y15.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERAS Yearly Revenue VS EstimatesERAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ERAS Yearly EPS VS EstimatesERAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ERAS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ERAS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERAS Price Earnings VS Forward Price EarningsERAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERAS Per share dataERAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.89%
EPS Next 3Y9.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ERAS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ERASCA INC

NASDAQ:ERAS (7/17/2025, 8:20:01 PM)

After market: 1.49 0 (0%)

1.49

+0.05 (+3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners76.45%
Inst Owner Change0%
Ins Owners7.35%
Ins Owner Change0%
Market Cap422.10M
Analysts85.71
Price Target6.12 (310.74%)
Short Float %8.43%
Short Ratio14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.72%
Min EPS beat(2)13.03%
Max EPS beat(2)14.41%
EPS beat(4)3
Avg EPS beat(4)1.81%
Min EPS beat(4)-55.48%
Max EPS beat(4)35.3%
EPS beat(8)6
Avg EPS beat(8)4.05%
EPS beat(12)9
Avg EPS beat(12)-11.88%
EPS beat(16)10
Avg EPS beat(16)-14.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)21.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.38%
EPS NY rev (1m)6.98%
EPS NY rev (3m)18.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.06
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-0.62
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.44%
ROE -39.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.99%
ROA(5y)-43.38%
ROE(3y)-45.53%
ROE(5y)-51.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.35
Quick Ratio 12.35
Altman-Z 0.85
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)200.09%
Cap/Depr(5y)425.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
EPS Next Y36.32%
EPS Next 2Y13.89%
EPS Next 3Y9.95%
EPS Next 5Y15.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.15%
EBIT Next 3Y-3.2%
EBIT Next 5YN/A
FCF growth 1Y3.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.77%
OCF growth 3YN/A
OCF growth 5YN/A